Lilly to Acquire Avid Radiopharmaceuticals

Indianapolis, IN and Philadelphia, PA -Eli Lilly and Company (NYSE: LLY) today announced that it has signed a definitive merger agreement to acquire Avid Radiopharmaceuticals, Inc., a privately held company developing novel molecular imaging compounds intended for the detection and monitoring of chronic human diseases.

More details please see: http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=527832